Enochian BioSciences is a pre-clinical stage biotechnology company. Co. engages in the research and development, and clinical trials of pharmaceutical and biological products for the human treatment of Human Immunodeficiency Virus (HIV) and cancer. Co.'s product candidates include: ENOB-HV-01 autologous cell therapy, which is a potential curative treatment for HIV; ENOB- HV-11 and ENOB-HV-12 vaccine, as a preventative vaccine and therapeutic vaccine, respectively; ENOB-HB-01 coopting Hepatitis B polymerase; and ENOB-DC-01, as a dendritic cell cancer vaccine designed to prevent relapse in colon cancer patients with no evidence of disease after resection and chemotherapy, among others. The ENOB stock yearly return is shown above.
The yearly return on the ENOB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ENOB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|